The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations.

The aim of this retrospective study was to determine the prevalence of lysosomal storage disorders (LSDs) in the Czech Republic. The data on cases diagnosed between 1975 and 2008 were collected and analyzed. The overall prevalence of LSDs in the Czech population (12.25 per 100,000) is comparable to that reported for the countries with well-established and advanced diagnostics of LSDs such as the Netherlands (14 per 100,000), Australia (12.9 per 100,000) and Italy (12.1 per 100,000). Relatively higher prevalence of LSDs was reported in the north of Portugal (25 per 100,000). Thirty-four different LSDs were diagnosed in a total of 478 individuals. Gaucher disease was the most frequent LSD with a birth prevalence of 1.13 per 100,000 births. The most frequent LSD groups were lipidoses, mucopolysaccharidoses, and neuronal ceroid lipofuscinoses, with combined prevalences of 5.0, 3.72, and 2.29 per 100,000 live births, respectively. Glycoproteinoses (0.57 per 100,000 live births), glycogenosis type II (0.37), and mucolipidoses (0.31) rarely occur in the Czech population, and a range of other LSDs have not been detected at all over the past three decades. Knowledge of the birth prevalence and carrier frequency of particular disorders is important in genetic counselling for calculation of the risk for the disorder in the other members of affected families. Earlier diagnosis of these disorders will permit timely intervention and may also result in lowering of the number of newborns with LSDs.

Introduction

Following the discovery of the lysosome by the Nobel Prize winner Christian de Duve in 1955 (De Duve et al. 1955), research into the biochemistry, molecular biology and pathology of the lysosomal system unravelled many of its functions.

Nowadays, genetic lysosomal storage disorders (LSDs) represent a group of about 50 disorders (Scriver et al. 2001; Staretz-Chacham et al. 2009). All of them are characterized by intralysosomal accumulation of compound(s), e.g., enzyme substrates or products, mishandled bioconjugates, or segregated cytoplasmic components, in a variety of cell types and tissues. Most LSDs result from a deficient enzyme activity caused by a mutation in the gene encoding either the relevant enzyme, protecting protein, protein activators, or the endoplasmic reticulum–Golgi enzyme systems responsible for proper protein posttranslational modification. However, some are caused by dysfunction of the lysosomal system itself due to mutations in genes encoding lysosomal membrane components or components closely associated with the lysosomal system (Saftig 2005; Jalanko and Braulke 2009). The number of lysosomal enzymes and non-catalytic proteins reported in the literature has steadily increased and, therefore, more defects in the lysosomal system are expected to be discovered. The progress in the research into LIMP-2 deficiency serves as a recent example (Balreira et al. 2008; Berkovic et al. 2008).

Overall frequencies of occurrence of LSDs have been reported for several countries (Meikle et al. 1999; Poorthuis et al. 1999; Applegarth et al. 2000; Dionisi-Vici et al. 2002; Pinto et al. 2004), while other reports focused on LSD groups (e.g., mucopolysaccharidoses, (MPS): Nelson et al. 2003; Baehner et al. 2005; Malm et al. 2008; lipidoses: Ozkara and Topcu 2004; neuronal ceroid lipofuscinoses, NCL: Claussen et al. 1992), or on particular LSDs (e.g., MPS I: Moore et al. 2008; metachromatic leukodystrophy and Krabbe disease: Heim et al. 1997). The frequency of LSDs as a group varies among populations from 7.6 to 25 per 100,000 (Meikle et al. 1999; Poorthuis et al. 1999; Applegarth et al. 2000; Dionisi-Vici et al. 2002; Pinto et al. 2004).

The aim of this study was to calculate the birth prevalence and carrier frequencies of LSDs in the Czech Republic population, and to compare our results with reported epidemiologic data from other populations.

Patients and methods

We analyzed data from individuals who had been diagnosed with a LSD at the Institute of Inherited Metabolic Disorders in Prague between 1975 and 2008. Our Institute is the only laboratory providing diagnostic testing for LSDs, including prenatal testing, in the Czech Republic. The patients had been referred to, or their blood samples had been sent to, the Institute by Departments of Paediatrics, Neurology, Haematology, Cardiology, Nephrology, Dermatology, Gastroenterology, Ophthalmology, Pathology, and Clinical Genetics from hospitals all over the country.

The initial diagnosis of most LSDs was based on demonstration of accumulated substrates (e.g., sphingolipids, oligosaccharides, or glycosaminoglycans) in tissues and/or body fluids using chromatographic or electrophoretic methods, or on histological proof of storage. The definite diagnosis was made by demonstrating the deficiency of the relevant enzyme and/or presence of pathogenic mutation, and/or by detection of undegraded substrate by loading tests in cell cultures. Mucolipidosis II was confirmed by detecting elevated activities of multiple lysosomal enzymes in serum and by molecular analysis. Patients with unspecified types of MPS or NCL, who had died before the availability of confirmatory tests, were also included in the birth prevalence calculation. Their diagnosis was based on biochemical analyses of storage compound, evaluation of clinical data, and histochemical and/or ultrastructural examinations of samples obtained at biopsy or autopsy.

For the calculation of the prevalence, we used the method published by Poorthuis et al. (1999). The prevalence was calculated as the total number of patients diagnosed with a particular LSD, divided by the total number of live births in the same period, as was the birth period of the diagnosed cases (i.e., the birth period is the interval between the year of the birth of the oldest patient and the year of the birth of the youngest patient). Birth prevalence was expressed as the number of patients per 100,000 live births. The total number of live births in particular years was calculated using birth rates taken from the Czech Statistical Office web page. To avoid underestimation, some patients were not included into the prevalence calculation (e.g., patients born before 1945 were excluded). If there was only one patient diagnosed with the disease, the prevalence was calculated using the number of live births (i.e., 4,261,897) in the examined period (i.e., between 1975 and 2008), as used previously by Pinto et al. (2004). Familial cases and 11 affected fetuses [Fabry disease (1), Niemann-Pick disease type C (1), MPS I (3), MPS III A (3) and MPS IV A (3)] were also included in the calculation of birth prevalence.

For some specific LSDs, the patient group consisted of subgroups with distinct clinical phenotypes (e.g., MLD, Gaucher disease). Using the method mentioned above, we calculated the prevalence of the subgroups separately, and the overall prevalence of the specific LSD was estimated as a sum of the prevalences in the subgroups (Poorthuis et al. 1999).

Calculation of the frequency of Fabry disease was done using two approaches, i.e., excluding and including female heterozygotes. Exclusion of heterozygotes (n = 78) enabled us to compare the prevalence to other reported male-specific prevalence data (Meikle et al. 1999; Poorthuis et al. 1999; Ozkara and Topcu 2004; Pinto et al. 2004). Fabry heterozygotes, who can be as severely affected as male patients, are nowadays classified as “patients” instead of “carriers of the defective gene” (Dobrovolny et al. 2005; Wang et al. 2007; Gibas et al. 2008). Therefore, we also calculated the prevalence including Fabry females.

Confidence intervals (95%) for the birth prevalences were estimated from the Poisson distribution using SISA (Simple Interactive Statistical Analysis) software (Uitenbroek 1997). Carrier frequency was calculated using the Hardy–Weinberg equation (Strachan and Read 2004).

Results

In the past three decades, a total of 478 patients have been diagnosed with one of 34 specific types of LSDs in the Czech Republic (Fig. 1). The number of diagnosed patients gradually increased during the study period, from less than 10 cases per year in the 1970s to 20–30 new cases diagnosed annually in recent years (Fig. 2). More than half of all LSD patients had a lipidosis, about one-quarter a mucopolysaccharidosis, and the remaining quarter suffered from NCL, GSD II, mucolipidoses, or glycoproteinoses (Fig. 1). The combined birth prevalence for all LSDs is 12.25 (95% CI 6.25–24.1) per 100,000 live births. Data on patients with lipidoses, mucopolysaccharidoses, and other LSDs detected during the study period, including carrier frequencies in the Czech population, are summarized in Tables 1, 2 and 3, respectively. Detailed data on the birth prevalence of specific disorders and their subtypes can be found in Tables 4, 5 and 6.

Fig. 1

Relative rate of lysosomal storage disorders in the Czech Republic. MPS Mucopolysaccharidosis, NCL neuronal ceroidlipofuscinosis, GSD II glycogenosis type II, ML mucolipidosis, GP glycoproteinosis, NPA/B/C Niemann-Pick A/B/C, MLD metachromatic leukodystrophy, CESD cholesterol ester storage disease, MSD multiple sulphatase deficiency, GM1 GM1 gangliosidosis, GM2 GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases), β-Man β-mannosidosis, α-Man α-mannosidosis, ISSD infantile sialic acid storage disease

Fig. 2

Number of live births (▲) and number of LSD diagnoses (♦) in the Czech population from 1975 to 2008. In 1985, electrophoretic analysis of glycosaminoglycans (ELFO GAG) and thin layer chromatography of oligosaccharides (TLC OLS) in urine were introduced. From 1990 onwards, enzyme assays for mucopolysaccharidoses and glycoproteinoses were gradually introduced. Nowadays, laboratory diagnostic methods for 45 LSDs are available (enzyme and DNA analyses, loading assays)

Table 1

Lipidoses: comparison of data in different populations

Disease	Czech Republic				Other countries
	No. of patients 1975–2008a	Prevalence per 100,000b	Poisson 95% confidence interval	Carrier frequencyc × 103	NL	Portugal	Australia	Turkey
					Prevalence per 100,000 live births
Gaucher (all types)	49	1.13	0.61–1.95	6.71	1.16	1.35	1.75	0.45
Niemann-Pick A/B	23	0.33	0.16–0.61	3.65	0.53	0.6	0.4
Niemann-Pick C	54	0.91	0.67–1.21	6.02	0.35	2.2	0.47
Fabry male	49	0.52 (1.0)d	0.38–0.69	0.01	0.21	0.12	0.86	0.015
Fabry female	78	0.77	0.60–0.98
Krabbe	15	0.40	0.21–0.68	4.0	1.35	1.21	0.71	1
MLD (all types)	25	0.69	0.29–1.38	5.26	1.42	1.85	1.09	1.43
CESD, Wolman	18	0.27	0.15–0.45	3.31			0.19
GM1 gangliosidosis	13	0.26	0.14–0.46	3.25	0.41	0.62	0.26	0.54
GM2 Tay-Sachs	10	0.30	0.14–0.55	3.45	0.41	3.13	0.5	0.23
GM2 Sandhoff	3	0.19	0.04–0.55	2.74	0.34	1.49	0.26	0.95
Lipidoses all types	259e/337f	5.0e/5.77f	2.79 (3.39)–8.53 (9.51)		6.2	12.6	6.6	4.6

NL Netherlands, MLD metachromatic leukodystrophy, CESD cholesteryl ester storage disease

aTotal number of patients diagnosed between 1975 and 2008

bData for prevalence calculations are in Table 4

cCarrier per 1 live birth

dMale live births only

eFabry females not included

fFabry females included

Table 2

Mucopolysaccharidoses: comparison of data in different populations

Disease	Czech Republic				Other countries
	No. of patients 1975–2008a	Prevalence per 100,000b	Poisson 95% confidence interval	Carrier frequencyc × 103	NL	Portugal	Australia	Germany
					Prevalence per 100,000 live births
MPS I	20	0.72	0.44–1.11	5.38	1.19	1.33	1.14	0.69
MPS II	22	0.43 (0.83)d	0.26–0.65	0.0085	0.67	1.09	0.74	0.64
MPS III A	18	0.47	0.27–0.75	4.31	1.16	0	0.88
MPS III B	1	0.02	0.0–0.13	0.97	0.42	0.72	0.47
MPS III C	5	0.42	0.14–0.99	4.12	0.21	0.12	0.07
MPS III D	0	0			0.1		0.10
MPS III (all types)	24	0.91	0.41–1.87		1.89	0.84	1.42	1.57
MPS IV A	14	0.71	0.38–1.22	5.35	0.22	0.6	0.59
MPS IV B	1	0.02	0.0–0.13	0.97	0.14	0	0
MPS IV (A + B)	15	0.73	0.38–1.35					0.38
MPS VI	2	0.05	0.01–0.18	1.40	0.15	0.42	0.43	0.23
MPS VII	1	0.02	0.0–0.13	0.97	0.24	0	0.05
MPS unspecifiede	32	0.60	0.39–0.87
MSD	3	0.26	0.05–0.77	3.24	0.05	0.48	0.07
MPS all types	119	3.72	1.94–6.93		4.5	4.8	4.44	3.53

NL Netherlands, MPS mucopolysaccharidosis, MSD multiple sulphatase deficiency

aTotal number of patients diagnosed between 1975 and 2008

bData for prevalence calculations are in Table 5

cCarrier per 1 live birth

dMale live births only

eUnspecified cases of MPS were diagnosed on the basis of analysis of glycosaminoglycan excreted in urine combined with the evaluation of clinical data. No material was available for enzyme and DNA analysis

Table 3

Glycoproteinoses, mucolipidoses, glycogenosis type II and neuronal ceroid lipofuscinoses: comparison of data in different populations

Disease	Czech Republic				Other countries
	No. of patients 1975–2008a	Prevalence per 100,000b	Poisson 95% confidence interval	Carrier frequencyc × 103	NL	Portugal	Australia
					Prevalence per 100,000 live births
α-Mannosidosis	4	0.38	0.10–0.98	3.92	0.09	0.12	0.1
β-Mannosidosis	2	0.16	0.02–0.59	2.56	0.13	0.12	0
ISSD	1	0.02	0.0–0.13	0.97	0.07	0	0.19
Fucosidosis	0				0.05	0	0
Aspartylglucosaminuria	0				0.13	1.72	0.05
α-N-acetyl-galactosaminidase def.	0				0.2	0	0
Galactosialidosis	0				0.04	0.77	0
Mucolipidosis I	3	0.07	0.01–0.20	1.66	0.05	0	0.02
Mucolipidosis II/III	3	0.22	0.05–0.65	2.98	0.24	0.81	0.31
Mucolipidosis IV	1	0.02	0.0–0.13	0.97
Glycogenosis type II (all)	12	0.37	0.13–0.81	3.86	2	0.17	0.69
NCL 1	2	0.19	0.02–0.70	2.79		0.17
NCL 2	28	0.36	0.24–0.52	3.79		0.07
NCL 3	2	0.27	0.03–0.96	3.27		0.48
NCL 4	1	0.02	0.0–0.13	0.97
NCL 5	2	0.21	0.03–0.77	2.92
NCL 6	1	0.02	0.0–0.13	0.97		1.43
NCL 7	18	0.85	0.49–1.36	5.81
NCL unspecifiedd	20	0.37	0.22–0.58
NCL (all types)	74	2.29	1.03–5.15			2.14

NL Netherlands, ISSD infantile sialic acid storage disease, NCL neuronal ceroid lipofuscinosis

aTotal number of patients diagnosed between 1975 and 2008

bData for prevalence calculations are in Table 6

cCarrier per 1 live birth

dUnspecified NCL were diagnosed on the basis of histochemical and ultrastructural examination of biopsy samples combined with the evaluation of clinical data. No material was available for enzyme and DNA analysis

Table 4

Lipidoses: data for calculation of birth prevalence

Disease	No. of patients 1975–2008a,b	Years of birth	No. of live births	No. of patientsc	Prevalence (1 per numbers of live births)	Prevalence per 100,000	Carrier frequencyd
Gaucher type I, early	12 (10)	1974–1996	3 090 902	12	257 575	0.39	254
Gaucher type I, late	29 (28)	1945–1980	5 956 028	24	248 168	0.40	249
Gaucher type II and IIIe	8 (8)	1980–1998	2 352 492	8	294 062	0.34	271
Gaucher (all types)	49			44	88 397	1.13	149
Niemann-Pick A	10 (8)	1963–2002	5 480 885	10	548 089	0.18	370
Niemann-Pick B + atypf	13 (11)	1948–1996	7 362 146	11	669 286	0.15	409
Niemann-Pick A/B	23			21	301 327	0.33	274
Niemann-Pick Cg	54 (45)	1965–2003	5 271 310	48	109 819	0.91	166
Fabryh	49 (24)	1945–2002	8 518 601	44	193 605	0.52	96 803
		Male	4 382 068	44	99 592	1.00n
Fabry female	78 (24)	1945–2005	8 812 161	68	129 591	0.77
Krabbei	15 (15)	1977–2002	3 249 150	13	249 935	0.40	250
MLD infantile	13 (11)	1970–1999	4 195 564	13	322 736	0.31	284
Juvenile	5 (4)	1970–2004	4 661 324	5	932 265	0.11	483
Adult	7 (7)	1968–1980	2 188 004	6	364 667	0.27	302
MLD (all types)	25			24	144 647	0.69	190
CESD, Wolmanj	18 (15)	1963–2002	5 480 885	15	365 392	0.27	302
GM1 gangliosidosis	13 (13)	1970–2003	4 563 660	12	380 305	0.26	308
GM2 Tay-Sachsk	10 (10)	1971–1992	3 362 889	10	336 289	0.30	290
GM2 Sandhoff	3 (3)	1992–2007	1 594 949	3	531 650	0.19	365
Lipidoses all types	259l/337m			234l/302m	20 000	5.0l/5.77m	71o

MLD Metachromatic leukodystrophy, CESD cholesteryl ester storage disease

aTotal number of patients diagnosed between 1975 and 2008

bNumber of families with particular disorder in parentheses

cNumber of patients taken for the calculation of birth prevalence. To avoid underestimation, some patients were not included into the prevalence calculation (e.g., patients born before 1945 were excluded). For prevalence definition, see “Patients and Methods”

dExpressed as 1 carrier per number of shown live births

eOne stillborn case

fNP type B in 6 slowly progressive visceral cases and atypical protracted neurovisceral phenotype in 7 cases [Pavlů-Pereira H, et al. J Inherit Metab Dis 2005;28:203–227]

gIncluding one case of NP type C2 [Elleder M. et al. Virchows Arch 2001;439:206–211]

hClassical phenotype in 43 male patients and cardiac variant in 6 male patients (two families) [Elleder M, et al. Cas Lek Cesk 1990;129:368–372]

iInfantile form in 12 patients, late infantile in 2 patients, and adult form in one patient [Kostalova E, et al. Ceska Slov Neurol Neurochir 2006;69/102:200–210]

jOne infantile patient (Wolman disease) and 17 juvenile and adult cases [Elleder M, et al. Cas Lek Cesk 1999;138:719–724]

kIncluding two adult patients

lFabry females not included

mFabry females included

nMale live births

oCarrier frequency of lipidoses except for Fabry disease

Table 5

Mucopolysaccharidoses: data for calculation of birth prevalence

Disease	No. of patients 1975–2008a,b	Years of birth	No. of live births	No. of patientsc	Prevalence (1 per number of live births)	Prevalence per 100,000	Carrier frequencyd
MPS I	20e (17)	1984–2008	2,772,559	20	138,628	0.72	186
MPS II	22 (19)	1969–2005	4,906,700	21	233,652	0.43	116,826
		Male	2,520,373	21	120,018	0.83f
MPS III A	18 (14)	1977–2006	3,648,541	17	214,620	0.47	232
MPS III B	1	1975–2008	4,261,897	1	4,261,897	0.02	1,032
MPS III C	5 (4)	1984–1992	1,179,745	5	235,949	0.42	243
MPS III (all types)	24			23	109,502	0.91	165
MPS IV A	14 (9)	1987–2003	1,826,473	13	140,498	0.71	187
MPS IV B	1	1975–2008	4,261,897	1	4,261,897	0.02	1,032
MPS IV (A + B)	15			14	136,986	0.73	185
MPS VI	2 (2)	1968–1995	4,115,057	2	2,057,529	0.05	717
MPS VII	1	1975–2008	4,261,897	1	4,261,897	0.02	1,032
MPS I–VII	84			81	34,909	2.86	93
MPS-unspecified	32 (27)	1960–1989	4,533,496	27	167,907	0.60	205
MSD	3 (1)	1962–1969	1,144,467	3	381,489	0.26	309
MPS all types	119			111	26,865	3.72	82g

MPS mucopolysaccharidosis, MSD multiple sulphatase deficiency

aTotal number of patients diagnosed between 1975 and 2008

bNumber of families with particular disorder in parentheses

cNumber of patients taken for the calculation of birth prevalence. To avoid underestimation, some patients were not included into the prevalence calculation (e.g., patients born before 1945 were excluded). For prevalence definition, see “Patients and Methods”

dExpressed as 1 carrier per number of shown live births

eHurler syndrom in 16 patients, Hurler/Scheie in 2 patients and Scheie syndrom in 2 patients

fMale live births

gCarrier frequency of MPS excluding MPS II

Table 6

Glycoproteinoses, mucolipidoses, glycogenosis type II and neuronal ceroidlipofuscinoses: data for calculation of birth prevalence

Disease	No. of patients 1975–2008a,b	Years of birth	No. of live births	No. of patientsc	Prevalence (1 per numbers of live births)	Prevalence per 100,000	Carrier frequencyd
α-Mannosidosis	4 (3)	1985–1992	1,042,804	4	260,701	0.38	255
β-Mannosidosis	2 (1)	1950–1956	1,223,386	2	611,693	0.16	391
ISSD	1	1975–2008	4,261,897	1	4,261,897	0.02	1,032
Mucolipidosis I	3e (2)	1969–1999	4,338,729	3	1,446,243	0.07	601
Mucolipidosis II/III	3 (3)	1994–2007	1,352,219	3	450,740	0.22	336
Mucolipidosis IV	1f	1975–2008	4,261,897	1	4,261,897	0.02	1,032
GP + ML (all types)	14			14	112,995	0.87	170
Glycogenosis type II infantile	6 (5)	1979–1999	2,614,075	6	435,679	0.23	330
Glycogenosis type II juvenile	6 (5)	1972–2002	4,167,930	6	694,655	0.14	417
Glycogenosis type II (all)	12			12	267,750	0.37	259
NCL 1	2 (2)	1970–1975	1,033,447	2	516,724	0.19	359
NCL 2	28 (25)	1949–2003	7,803,068	28	278,681	0.36	264
NCL 3	2 (2)	1979–1983	749,520	2	374,760	0.27	306
NCL 4	1	1975–2008	4,261,897	1	4,261,897	0.02	1,032
NCL 5	2 (1)	1983–1989	935,553	2	467,777	0.21	342
NCL 6	1	1975–2008	4,261,897	1	4,261,897	0.02	1,032
NCL 7	18 (16)	1985–2002	2,002,025	17	117,766	0.85	172
NCL-unspecified	20 (17)	1965–1999	4,903,214	18	272,401	0.37	261
NCL (all types)	74			71	43,551	2.29	104

ISSD infantile sialic acid storage disease, GP glycoproteinosis, ML mucolipidosis, NCL neuronal ceroid lipofuscinosis

aTotal number of patients diagnosed between 1975 and 2008

bNumber of families with particular disorder in parentheses

cNumber of patients taken for the calculation of birth prevalence. To avoid underestimation, some patients were not included into the prevalence calculation (e.g. patients born before 1945 were excluded). For prevalence definition see “Patients and Methods”

dExpressed as 1 carrier per number of shown live births

eOne infantile patient and two juvenile siblings with cherry-red spot myoclonus syndrome [Ledvinova J, et al. J Inherit Metab Dis 1994;17:118–119]

fAtypical case of ML IV with ocular restricted phenotype [Dobrovolny R, et al. Am J Ophthalmol 2007; 143:663–671]

To date, no individuals in the Czech population have been conclusively diagnosed with Farber disease, Schindler disease, Danon disease, Sanfilippo D disease, galactosialidosis, fucosidosis, aspartylglucosaminuria, or prosaposin, saposins, or GM2 activator protein deficiencies.

Discussion

The overall prevalence of LSDs in the Czech population (12.25 per 100,000), which represents a typical Central European population, is comparable to prevalences reported for Australia (12.9 per 100,000), the Netherlands (14 per 100,000) and Italy (12.1 per 100,000) (Meikle et al. 1999; Poorthuis et al. 1999; Dionisi-Vici et al. 2002). The higher prevalence of LSDs reported for the northern Portuguese population (25 per 100,000) might reflect the relative geographic isolation and more extensive studying of that particular population of this region (Pinto et al. 2004). The most frequent single LSD is Gaucher disease in the Czech Republic, Italy and Australia, GM2 gangliosidosis in Portugal, and Pompe disease in the Netherlands.

In the Czech population, lipidoses were most frequently diagnosed (5.0 per 100,000 live births), followed by MPS (3.72) and NCL (2.29). In addition to the LSD diagnoses in Czech patients, 96 cases from Slovakia were confirmed at our Institute during the studied period; 41% with lipidoses, 39% with MPS, and 20% with GSD II or NCLs. These Slovakian patients have not been included in our prevalence calculations as former Czechoslovakia was divided into two independent states, the Czech Republic and the Slovak Republic, in 1993. Interestingly, the four cases of prosaposin deficiency so far diagnosed at our Institute came from neighboring populations (Slovak, German) (Hulkova et al. 2001; Elleder et al. 2005; Kuchar et al. 2009).

The birth prevalence of the most frequent LSD in the Czech Republic, Gaucher disease, is 1.13 per 100,000 live births, followed by Niemann-Pick C (0.91), MPS III (0.91), MPS IV (0.73), and MPS I (0.72). Comparison of these prevalences to those in selected foreign populations (Tables 1, 2 and 3) is complicated by the differences in methods used for calculation. When we compared the calculations of prevalence in the Czech population based on the method of Poorthuis et al. (1999) used in this study (see “Patients and Methods”) to the method reported by Meikle et al. (1999) (the prevalence calculated as the number of patients divided by the total number of live births during the study period), the calculations resulted in underestimation or overestimations of some individual disorders. This is the case for disorders with delayed onset (e.g., frequencies of Fabry disease were 0.52 and 1.14 per 100,000, and frequencies of cholesterol ester storage disease were 0.27 and 0.42, if calculated using the methods of Poorthuis et al. (1999) and Meikle et al. (1999), respectively). Also, unavailability of some diagnostic methods during the study period (some methods were introduced as late as the 1990s) may explain some discrepancies found in our calculations using the two methods. Although prevalence values for some disorders calculated using either of the methods were within the confidence intervals (data not shown), for other disorders prevalence values fell outside this interval (e.g., the frequencies differed for MPS III C (0.42 and 0.11 per 100,000), MPS IVA (0.71 and 0.32), NCL 2 (0.36 and 0.65) and NCL 7 (0.85 and 0.42), if calculated according to the methods used by Poorthuis et al. (1999) and Meikle et al. (1999), respectively).

Thus, establishment of standard rules for calculation of birth prevalence-a defined term in clinical epidemiology-is highly recommended. This would enable more reliable comparison of data from different populations. Based on our experience, the calculation of the ratio of the number of patients to the number of live births during the patients’ births period (Poorthuis et al. 1999) fits well to the definition of prevalence. Underestimation of the birth prevalence may result from lack of recognition of early clinical signs and symptoms or phenotypic diversity, including adult forms of the disease (e.g., Fabry disease, adult Krabbe disease, adult MLD, cholesteryl ester storage disease, and adult GSD II). Thus, the calculated birth prevalence is probably the lowest estimate as the diagnosis is commonly delayed for years. Screening studies have shown that certain groups of patients, for example individuals with renal failure on haemodialysis, may harbor missed Fabry patients (Nakao et al. 2003; Kotanko et al. 2004). The nationwide screening study among 3,370 chronic haemodialysis patients in the Czech Republic disclosed four previously unrecognized Fabry males and one female from five unrelated families. Subsequent family screening ascertained Fabry disease in another 12 individuals, including 8 females (Merta et al. 2007). Patients with unexplained cardiomyopathy represent another group at risk of having Fabry disease where screening is justified (Monserrat et al. 2007). Such LSD screening initiatives for selected LSDs will contribute to the identification of the true prevalence of these disorders (Spada et al. 2006; Chien et al. 2008).

Fabry heterozygotes have not been included in the calculation of birth prevalence in previous reports (Meikle et al. 1999; Poorthuis et al. 1999; Pinto et al. 2004). However, they commonly develop clinical symptoms and severe complications, generally a few years later, as in affected men (Deegan et al. 2006; Wilcox et al. 2008). When we included Fabry heterozygotes in the calculations, the prevalence of Fabry disease increased by 2.5 times to 1.29 per 100,000 live births, that of lipidoses from 5.0 to 5.77 per 100,000 and the overall prevalence of LSDs reached 13.02 per 100,000 (Table 4). Therefore, we propose that Fabry heterozygotes ought to be included in the calculation of the birth prevalence of Fabry disease.

Reliable calculation of the birth prevalence is dependant on a correctly defined pathogenic cause underlying the condition. Recent molecular studies have provided evidence for at least ten separate genetic loci (CLN1–CLN10) for NCL (Peltonen et al. 2000; Siintola et al. 2007). These new findings necessitated reclassification of our 37 cases that had formerly been provisionally classified as NCL6 into NCL5, NCL6, and NCL7 subgroups. The latter turned out to be of high prevalence in the Roma Gypsy population (Kousi et al. 2009). About a quarter of the NCL cases remain unspecified due to the lack of material suitable for mutation analysis.

Athough specific LSDs are generally reckoned to be rare disorders, as a group of inherited metabolic disorders they are quite common, as seen from published and our data. The information on birth prevalencies of LSDs is available from countries with a long tradition of diagnosis of LSDs; however, for most populations, these date are missing. Epidemiological data on these disorders are important in genetic counselling for calculation of the risk for the disorders in the other members of affected families and subsequently for the public health care systems.

Importantly, awareness of the clinical aspects of these life-threatening and progressively disabling genetic diseases among the medical community should increase, allowing earlier diagnosis. In turn, this will offer an opportunity for early therapeutic intervention. Dependant on the diagnosed disorder, such intervention may include enzyme replacement therapy, bone marrow transplantation, or other current or future therapies. Last but not least, it should be borne in mind that genetic counselling and prenatal diagnosis in families affected by a genetic metabolic disorder still form the basic strategy for lowering the number of patients with these severe disorders.